News•Apr 15, 2026
Weight Loss Drugs: What Athletes Need to Know About GLP-1s
GLP‑1 agonists such as semaglutide (Ozempic, Wegovy) and tirzepatide have surged in popularity for weight loss, prompting off‑label use among athletes. While the World Anti‑Doping Agency currently permits GLP‑1s, it is actively monitoring the class to decide if future bans are warranted. The FDA only authorizes these drugs for type‑2 diabetes or medically‑supervised obesity treatment, and no generic or over‑the‑counter versions exist. Unapproved online versions pose serious safety risks, including mislabelled ingredients and severe side effects.
